Sergey Gorelikov

Sergey Gorelikov

Auto-generated profile, based on publicly available information

Sergey Gorelikov

Russian Children’s Clinical Hospital – branch of the Pirogov Russian National Research Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2025 in Child's Nervous System
Verified
Journal Article
Open access
PDF file
RMRoni Mai
Roni Mai
DRDmitriy Reshchikov
Dmitriy Reshchikov
VPVladimir Popov
Vladimir Popov
SGSergey Gorelikov
Sergey Gorelikov
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
SMSvetlana Mikhaylova
Svetlana Mikhaylova
Purpose: We present two clinical cases of frameless, neuronavigated gene therapy with eladocagene exuparvovec for aromatic L-amino acid decarboxylase (AADC) deficiency in pediatric patients, detailing the targeted bilateral microdose delivery of viral vectors into the putamen and highlighting the feasibility and challenges of this approach in managing a rare neurometabolic disorder. Methods: Two patients with a confirmed diagnosis of AADCD underwent frameless stereotactic gene therapy. High-resolution 3 T MRI-guided trajectories were planned for the targeted bilateral putaminal infusion of 0.32 ml of eladocagene exuparvovec (AAV2-hAADC). The agent was delivered via a SmartFlow Neuro Ventricular Cannula in a “Z-pattern,” retracting the cannula 2 mm every 9 min to achieve controlled microdosing. Results: Accurate frameless drug delivery was achieved in a shorter time than frame-based approaches, with no intraoperative or postoperative complications. One patient showed a small post-ischemic cyst on the 1-month follow-up MRI, without any neurological deficits. Over 2 months, both patients demonstrated reduced oculogyric crises, diminished hyperkinesis, and improved head control, with no significant adverse events. Conclusion: Frameless, neuronavigated gene therapy for AADC deficiency proved both feasible and safe, with early clinical improvements observed in motor function and symptom control. This technique offers a promising alternative to frame-based methods and expands treatment options for this rare neurometabolic disorder.

6 March 2026 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
DRDmitriy A. Reshchikov
Dmitriy A. Reshchikov
RMR. B. Mai
R. B. Mai
SMS. V. Mikhaylova
S. V. Mikhaylova
SGS. V. Gorelikov
S. V. Gorelikov
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
VPV. V. Palm
V. V. Palm
Aim. To present the authors’ experience in implementing a frameless stereotactic infusion technique of a gene preparation using an adeno-associated vectored virus into the subcortical structures of the brain in children with aromatic L-amino acid decarboxylase deficiency (AADCd), with an emphasis on technical and organizational aspects. Materials and methods. From November 2024 to December 2025, six bilateral infusions of eladocagen exuparvovec (Upstaza®) were administered into the putamen of children with genetically confirmed AADCd in the Department of Pediatric Neurosurgery of the Russian Children’s Clinical Hospital. The key stages of patient selection, regulatory support, preoperative planning based on brain magnetic resonance imaging data, features of frameless navigation, the Z-shaped convection-enhanced infusion technique, and measures for preventing intra- and postoperative complications are described. The analysis of clinical outcomes is deliberately not presented in this work and is planned for a separate publication after increasing the sample size and follow-up observation. Results. In all 6 cases, accurate drug delivery to the putamen was ensured in accordance with preoperative planning, and no intraoperative complications were observed. Early postoperative magnetic resonance imaging monitoring revealed no clinically significant hemorrhagic or ischemic brain damage. In all cases, improvements in motor and autonomic symptoms of varying severity were noted during the first months of follow-up. Conclusion. The presented experience demonstrates the technical feasibility and safety of frameless stereotactic gene therapy for AADCd in children in a Federal Center setting. The proposed method can serve as the basis for a national treatment protocol for AADCd and the establishment of a reference center for gene therapy for central nervous system diseases.

24 October 2026 in Archives of Pediatrics and Pediatric Surgery
Verified
Journal Article
Open access
PDF file
DRD. A. Reshchikov
D. A. Reshchikov
SMS. V. Mikhailova
S. V. Mikhailova
EPE. E. Petryaikina
E. E. Petryaikina
EPE. A. Putilina
E. A. Putilina
SGS. V. Gorelikov
S. V. Gorelikov
КГК. К. Гаджиева
К. К. Гаджиева
L-aromatic amino acid decarboxylase deficiency (AADC) is a rare autosomal recessive neurometabolic disorder caused by biallelic versions in the DDC gene and resulting in severe dopamine and serotonin deficiency Until recently, treatment was limited to exclusively symptomatic approaches and did not influence the poor prognosis. This review provides a chronological reconstruction of the development of therapeutic strategies, from early ineffective pharmacological regimens to modern pathogenetic gene therapy using the recombinant adeno-associated viral vector AAV2hAADC. Particular attention is paid to the neurosurgical component: the transition from frame stereotaxy and isolated intraputamenal infusion to contactless neuronavigation and convection-enhanced delivery under MRI guidance. The Russian experience of implementing a frameless stereotactic technique at the Russian Children’s Clinical Hospital is separately reviewed. Key clinical studies confirming the efficacy and safety of the approach are discussed, as are regulatory milestones leading to the approval of eladocagen exuparvovec (Upstaza in Europe in 2022, Kebilidi in the USA in 2024) Prospects and unresolved issues, including the optimal therapeutic window and long-term safety, are addressed.